CNAT News and Press, Conatus Pharmaceuticals From 10/25/18

SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the third quarter ended September 30, 2018, after the market close on Thursday, November 1, 2018. Conatus will host a conference call and audio w...

Editor's note: Seeking Alpha is proud to welcome Dummy Pill Capital as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Introd...

Preface Within my exclusive marketplace, The Formula , I look for assets that provide therapeutic differentiation (have superior efficacy and safety, serve unmet needs, have limited competition, etc.). Conatus (CNAT), in collaboration with Novartis (NVS), is developing emricasan for a v...

"Success is the result of perfection, hard work, learning from failure and persistence" - Colin Powell Background The conclusion to the 20-year persistence by inventors, Drs. Mento and Spada, to establish the clinical value of emricasan (IDN-6556, PF-03491390) in liver diseases is...

SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that two abstracts – one addressing clinical results with the company’s pan-caspase inhibitor, emricasan, and one addressing preclinical results with the company’s pan-...

Biotechs developing treatments for nonalcoholic steatohepatitis (NASH) and other fatty liver diseases are seeing some action following the release of abstracts for November's Liver Meeting in San Francisco. More news on: NGM Biopharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals...

Quick Take Tiziana Life Sciences plc ( TLSA ) is seeking to raise $16 million in a U.S. IPO, according to an amended registration statement . The company is advancing a pipeline of therapeutic candidates for various cancers and immune diseases. TLSA is developing promising treatments ...

NEW YORK, NY / ACCESSWIRE / September 25, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) , a biotechnology company, fo...

SAN DIEGO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, will host an invitation-only symposium on portal hypertension for institutional investors and research anal...

Money won't create success, the freedom to make it will - Nelson Mandela Investment Thesis Pfizer Inc. ( PFE ), a large-cap ($251B) multi-billion global biopharmaceutical company, gained pharmaceutical celebrity status when sildenafil citrate marketed globally as Viagra was app...